Annik Prat

14.9k total citations · 4 hit papers
101 papers, 8.3k citations indexed

About

Annik Prat is a scholar working on Molecular Biology, Surgery and Cell Biology. According to data from OpenAlex, Annik Prat has authored 101 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Molecular Biology, 43 papers in Surgery and 21 papers in Cell Biology. Recurrent topics in Annik Prat's work include Lipoproteins and Cardiovascular Health (41 papers), Peptidase Inhibition and Analysis (16 papers) and Cellular transport and secretion (15 papers). Annik Prat is often cited by papers focused on Lipoproteins and Cardiovascular Health (41 papers), Peptidase Inhibition and Analysis (16 papers) and Cellular transport and secretion (15 papers). Annik Prat collaborates with scholars based in Canada, France and United States. Annik Prat's co-authors include Nabil G. Seidah, Jadwiga Marcinkiewicz, Suzanne Benjannet, Rachid Essalmani, Ann Chamberland, Michel Chrétien, Steve Poirier, L. Alexandra Wickham, Jean Davignon and Nasha Nassoury and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Annik Prat

97 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation

2003 953 citations Nabil G. Seidah, Suzanne Benjannet et al. profile →
The biology and therapeutic targeting of the proprotein convertases

2012 622 citations Nabil G. Seidah, Annik Prat profile →
NARC-1/PCSK9 and Its Natural Mutants

2004 532 citations Suzanne Benjannet, Rachid Essalmani et al. Journal of Biological Chemistry profile →
Statins Upregulate PCSK9 , the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia

2004 518 citations Ann Chamberland, Hanny Wassef et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Annik Prat Canada	43	5.0k	2.8k	1.5k	1.2k	980	101	8.3k
L. Alexandra Wickham United States	26	1.3k 0.3×	1.1k 0.4×	323 0.2×	358 0.3×	347 0.4×	41	3.6k
Steven M. Lipkin United States	39	446 0.1×	3.9k 1.4×	1.5k 1.0×	441 0.4×	358 0.4×	107	6.2k
Arthur Sands United States	35	943 0.2×	4.0k 1.4×	672 0.5×	209 0.2×	405 0.4×	62	6.5k
R. Stephanie Huang United States	39	479 0.1×	4.5k 1.6×	2.8k 1.9×	733 0.6×	175 0.2×	184	7.5k
Barry D. Nelkin United States	52	539 0.1×	5.1k 1.8×	899 0.6×	352 0.3×	434 0.4×	110	8.2k
Rakesh Kumar United States	47	290 0.1×	4.6k 1.6×	1.2k 0.8×	428 0.3×	816 0.8×	160	7.1k
Yasuo Miyoshi Japan	52	714 0.1×	4.6k 1.6×	2.3k 1.5×	478 0.4×	805 0.8×	252	9.3k
Ilsa M. Coleman United States	46	275 0.1×	3.8k 1.3×	2.2k 1.5×	582 0.5×	489 0.5×	111	7.8k
Peter C. Lucas United States	43	1.2k 0.2×	4.2k 1.5×	2.4k 1.6×	1.7k 1.4×	412 0.4×	163	8.4k
Marc G. Denis France	40	409 0.1×	2.1k 0.8×	1.1k 0.8×	811 0.7×	190 0.2×	176	4.9k

Countries citing papers authored by Annik Prat

Since Specialization

Citations

This map shows the geographic impact of Annik Prat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annik Prat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annik Prat more than expected).

Fields of papers citing papers by Annik Prat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annik Prat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annik Prat. The network helps show where Annik Prat may publish in the future.

Co-authorship network of co-authors of Annik Prat

This figure shows the co-authorship network connecting the top 25 collaborators of Annik Prat. A scholar is included among the top collaborators of Annik Prat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annik Prat. Annik Prat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Prat, Annik, et al.. (2025). Chromatin accessibility and gene expression in the parasite Trichomonas vaginalis. BMC Infectious Diseases. 25(1). 1365–1365.

Roubtsova, Anna, Hadi Bayat, Alexandra Evagelidis, et al.. (2025). Blockade of colon cancer metastasis via single and double silencing of PCSK7/PCSK9: enhanced T cells cytotoxicity in mouse and human. Journal for ImmunoTherapy of Cancer. 13(6). e011364–e011364.

Moreau, F., Aurélie Thedrez, Audrey Ayer, et al.. (2021). PCSK9 is not secreted from mature differentiated intestinal cells. Journal of Lipid Research. 62. 100096–100096. 6 indexed citations

Peyot, Marie‐Line, Anna Roubtsova, Roxane Lussier, et al.. (2021). Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1866(8). 158968–158968. 25 indexed citations

Lebeau, Paul, Hanny Wassef, Jae Hyun Byun, et al.. (2020). The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury. Journal of Clinical Investigation. 131(2). 30 indexed citations

Paquette, Martine, Dany Gauthier, Ann Chamberland, et al.. (2020). Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis. Clinical Biochemistry. 77. 20–25. 29 indexed citations

Seidah, Nabil G., Annik Prat, Angela Pirillo, Alberico L. Catapano, & Giuseppe Danilo Norata. (2019). Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. Cardiovascular Research. 115(3). 510–518. 63 indexed citations

Essalmani, Rachid, Delia Susan‐Resiga, Johann Guillemot, et al.. (2017). Thrombin activation of protein C requires prior processing by a liver proprotein convertase. Journal of Biological Chemistry. 292(25). 10564–10573. 7 indexed citations

Coriati, Adèle, Guillaume F. Bouvet, Annik Prat, et al.. (2017). Proprotein Convertase Subtilisin/Kexin type 9 affects insulin but not lipid metabolism in cystic fibrosis. Clinical and investigative medicine. 40(2). E59–E65. 1 indexed citations

10.

Szumska, Dorota, et al.. (2017). Pcsk5 is required in the early cranio-cardiac mesoderm for heart development. BMC Developmental Biology. 17(1). 6–6. 8 indexed citations

11.

Seidah, Nabil G., Marianne Abifadel, Stefan Prost, Cathérine Boileau, & Annik Prat. (2016). The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. Pharmacological Reviews. 69(1). 33–52. 88 indexed citations

12.

Butkinaree, Chutikarn, Maryssa Canuel, Rachid Essalmani, et al.. (2015). Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. Journal of Biological Chemistry. 290(30). 18609–18620. 42 indexed citations

13.

Choi, Seungbum, Ujala Srivastava, Blake R. Peterson, et al.. (2013). Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9. Lipids in Health and Disease. 12(1). 112–112. 26 indexed citations

14.

Awan, Zuhier, Maxime Denis, Dana Bailey, et al.. (2011). The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. Atherosclerosis. 219(2). 455–462. 57 indexed citations

15.

Essalmani, Rachid, Delia Susan‐Resiga, Ann Chamberland, et al.. (2010). In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9. Journal of Biological Chemistry. 286(6). 4257–4263. 126 indexed citations

16.

Sun, Xiaowei, Rachid Essalmani, Nabil G. Seidah, & Annik Prat. (2009). The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model. Molecular Cancer. 8(1). 73–73. 23 indexed citations

17.

Zaid, Ahmed, Anna Roubtsova, Rachid Essalmani, et al.. (2008). Proprotein convertase subtilisin/kexin type 9 (PCSK9). Hepatology. 48(2). 646–654. 332 indexed citations

18.

Poirier, Steve, Gaétan Mayer, Suzanne Benjannet, et al.. (2007). The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2. Journal of Biological Chemistry. 283(4). 2363–2372. 381 indexed citations

19.

Prat, Annik, et al.. (2004). Nardilysin, A Basic Residues Specific Metallopeptidase That Mediates Cell Migration and Proliferation. Protein and Peptide Letters. 11(5). 501–508. 17 indexed citations

20.

Chesneau, Valérie, Ágnes Balogh, Catherine Joulie, et al.. (2000). N-arginine dibasic convertase (nardilysin) isoforms are soluble dibasic-specific metalloendopeptidases that localize in the cytoplasm and at the cell surface. Biochemical Journal. 349(2). 587–587. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact